EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ZYME, ANAB, AKTS, CGON, ETON, and represent 73.54% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$68M), TRAX (+$64M), FULC (+$24M), LEGN (+$23M), STOK (+$21M), ATRA (+$17M), AURA (+$12M), Odyssey Therapeutics (+$10M), PHVS (+$8.1M), NRIX (+$6.6M).
- Started 9 new stock positions in AARD, TRAX, Eloxx Pharmaceuticals, Odyssey Therapeutics, FULC, LEGN, AURA, NRIX, PHVS.
- Reduced shares in these 10 stocks: , Centessa Pharmaceuticals (-$255M), CRNX (-$156M), XNCR (-$26M), RLAY (-$23M), MBX (-$21M), ERAS (-$10M), REPL (-$7.7M), MREO, PRLD.
- Sold out of its positions in Centessa Pharmaceuticals, CRNX, IBIO, PRLD, REPL, XNCR, JAZZ.
- EcoR1 Capital was a net seller of stock by $-571M.
- EcoR1 Capital has $2.1B in assets under management (AUM), dropping by -12.71%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 31 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Zymeworks Del (ZYME) | 29.2 | $600M | 23M | 26.14 |
|
|
| Anaptysbio Inc Common (ANAB) | 25.9 | $532M | 7.9M | 67.50 |
|
|
| Aktis Oncology (AKTS) | 7.6 | $156M | 4.8M | 32.23 |
|
|
| Cg Oncology (CGON) | 7.1 | $146M | +86% | 2.1M | 71.05 |
|
| Eton Pharmaceuticals (ETON) | 3.8 | $79M | 2.2M | 36.20 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 3.7 | $76M | 1.4M | 54.54 |
|
|
| Oric Pharmaceuticals (ORIC) | 3.5 | $73M | 6.7M | 10.83 |
|
|
| First Tracks Biotherapeutics Ord Shs Added (TRAX) | 3.1 | $64M | NEW | 3.2M | 20.12 |
|
| Lakefront Biotherapeutics Nv Spon Adr | 2.4 | $50M | 1.7M | 29.98 |
|
|
| Neurogene (NGNE) | 1.9 | $40M | 1.3M | 31.45 |
|
|
| Stoke Therapeutics (STOK) | 1.2 | $24M | +635% | 735k | 32.72 |
|
| Fulcrum Therapeutics (FULC) | 1.2 | $24M | NEW | 6.5M | 3.66 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.1 | $23M | NEW | 800k | 28.88 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 1.0 | $22M | 2.8M | 7.62 |
|
|
| Mbx Biosciences (MBX) | 1.0 | $21M | -50% | 389k | 55.20 |
|
| Zenas Biopharma (ZBIO) | 1.0 | $20M | 790k | 25.38 |
|
|
| Atara Biotherapeutics Com New (ATRA) | 0.9 | $18M | +1458% | 1.6M | 11.48 |
|
| Relay Therapeutics (RLAY) | 0.6 | $13M | -63% | 698k | 18.71 |
|
| Aura Biosciences (AURA) | 0.6 | $12M | NEW | 1.7M | 7.10 |
|
| Odyssey Therapeutics Common Stock Added | 0.5 | $10M | NEW | 556k | 18.71 |
|
| Eikon Therapeutics (EIKN) | 0.5 | $9.6M | 733k | 13.05 |
|
|
| Pharvaris N V (PHVS) | 0.4 | $8.1M | NEW | 235k | 34.58 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $7.0M | 1.2M | 5.90 |
|
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $6.8M | 625k | 10.85 |
|
|
| Nurix Therapeutics (NRIX) | 0.3 | $6.6M | NEW | 270k | 24.26 |
|
| Erasca (ERAS) | 0.3 | $6.0M | -63% | 330k | 18.32 |
|
| Eloxx Pharmaceuticals Com New Added | 0.3 | $5.6M | NEW | 400k | 13.88 |
|
| Aardvark Therapeutics (AARD) | 0.1 | $2.4M | NEW | 411k | 5.76 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.1 | $2.1M | 200k | 10.64 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.0 | $318k | -92% | 1.0M | 0.32 |
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $115k | 4.4k | 25.95 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2026 Q2 filed Aug. 14, 2026
- EcoR1 Capital 2026 Q1 filed May 15, 2026
- EcoR1 Capital 2025 Q4 filed Feb. 17, 2026
- EcoR1 Capital 2025 Q3 filed Nov. 14, 2025
- EcoR1 Capital 2025 Q2 filed Aug. 14, 2025
- EcoR1 Capital 2025 Q1 filed May 15, 2025
- EcoR1 Capital 2024 Q4 filed Feb. 14, 2025
- EcoR1 Capital 2024 Q3 filed Nov. 14, 2024
- EcoR1 Capital 2024 Q2 filed Aug. 14, 2024
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022